Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Structure and Functions of the Urokinase Receptor

  • Pia RagnoEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_536


Historical Background

The receptor (uPAR) for the urokinase-type plasminogen activator (uPA) was firstly identified in 1985 on the surface of monocyte-like cells but only in 1990 uPAR protein was purified and cDNA cloned and sequenced. The first role proposed for uPAR was the focusing of the uPA proteolytic activity on the cell membrane, thus allowing cell migration through the extracellular matrix (ECM), without affecting the general architecture of the tissue. Since then, a large body of evidence clearly showed various roles for uPAR, independent of uPA enzymatic activity. In fact, uPAR is able to transduce proliferation, differentiation, adhesion, and migration signals into the cells, despite the absence of a transmembrane region and a cytosolic tail. However, the ability of uPAR to focus uPA activity on the cell membrane attributed to this specific receptor a key role in the plasminogen...

This is a preview of subscription content, log in to check access.


  1. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski LERK. (MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 2003;63:1684–95.PubMedPubMedCentralGoogle Scholar
  2. Balsara RD, Ploplis VA. Plasminogen activator inhibitor-1: the double-edged sword in apoptosis. Thromb Haemost. 2008;100:1029–36.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett. 2010;584:1923–30.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Carriero MV, Franco P, Vocca I, Alfano D, Longanesi-Cattani I, Bifulco K, Mancini A, Caputi M, Stoppelli MP. Structure, function and antagonists of urokinase-type plasminogen activator. Front Biosci. 2009;(14):3782–94.Google Scholar
  5. Castellino FJ, Ploplis VA. Structure and function of the plasminogen/plasmin system. Thromb Haemost. 2005;93:647–54.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Gargiulo L, Longanesi-Cattani I, Bifulco K, Franco P, Raiola R, Campiglia P, Grieco P, Peluso G, Stoppelli MP, Carriero MV. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide. J Biol Chem. 2005;280:25225–32.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Irigoyen JP, Muñoz-Cánoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol Life Sci. 1999;56:104–32.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Kjaergaard M, Hansen LV, Jacobsen B, Gardsvoll H, Ploug M. Structure and ligand interactions of the urokinase receptor (uPAR). Front Biosci. 2008;(13):5441–61.CrossRefGoogle Scholar
  9. Le Y, Murphy PM, Wang JM. Formyl-peptide receptors revisited. Trends Immunol. 2002;23:541–8.PubMedPubMedCentralCrossRefGoogle Scholar
  10. Madsen CD, Sidenius N. The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur J Cell Biol. 2008;87:617–29.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Margheri F, Manetti M, Serratì S, Nosi D, Pucci M, Matucci-Cerinic M, Kahaleh B, Bazzichi L, Fibbi G, Ibba-Manneschi L, Del Rosso M. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum. 2006;54:3926–38.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Medcalf RL, Stasinopoulos SJ. The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2. FEBS J. 2005;272:4858–67.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Montuori N, Visconte V, Rossi G, Ragno P. Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb Haemost. 2005;93:192–8.PubMedPubMedCentralCrossRefGoogle Scholar
  14. Montuori N, Bifulco K, Carriero MV, La Penna C, Visconte V, Alfano D, Pesapane A, Rossi FW, Salzano S, Rossi G, Ragno P. The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor. Cell Mol Life Sci. 2010. doi:10.1007/s00018-010-0564-7.CrossRefPubMedPubMedCentralGoogle Scholar
  15. Nagamine Y, Medcalf RL, Muñoz-Cánoves P. Transcriptional and potsttranscriptional regulation of the plasminogen activator system. Thromb Haemost. 2005;93:661–75.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Ragno P. The urokinase receptor: a ligand or a receptor? Story of a sociable molecule. Cell Mol Life Sci. 2006;63:1028–37.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Ragno P, Blasi F. uPAR and proteases in mobilization of hematopoietic stem cells. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF, editors. The Cancerdegradome. New York: Springer; 2008. p. 433–50.Google Scholar
  18. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost. 2009;7:4–13.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010;11:23–36.PubMedPubMedCentralCrossRefGoogle Scholar
  20. Tang CH, Wei Y. The urokinase receptor and integrins in cancer progression. Cell Mol Life Sci. 2008;65:1916–32.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of Chemistry and BiologyUniversity of SalernoFisciano, SalernoItaly